SMPT VALUATION AND **SMART-ACT™** PROGRAM PROJECTIONS

ABOUT SMPT	
Token Symbol	SMPT
Type	ERC-1404 security compliant token
Total Supply	1,000,000,000 (100%)
Tokens For Public	700,000,000 (70%)
Retention by Issuer's staff and partners	50,000,000 (5%)
Retention by Issuer	250,000,000 (25%)
Secondary Market	To be disclosed
Issuer	Smart Pharmaceutical Limited Partnership
Technology Partner	SMPT token co-developed with Aenco Solutions (www.aencoin.com)

PROJECTED SMPT INTRINSIC VALUE (US$) PER TOKEN[1]



Token backed by the **Smart-ACT™**

A systematic and perpetual pipeline of **clinical assets targeting**:

ORPHAN DISEASES; AND

UNMET MEDICAL NEEDS!

Year-end	Smart-ACT™ Program Valuation (US$ mil)	Value per SMPT token (US$)	Cumulative Candidates Emerging from Validation	Cumulative Clinical Assets in Pipeline
2019	$520.40	$0.08	3	-
2020	$3,277.20	$0.47	10	1
2021	$16,315.10	$2.34	17	2
2022	$29,349.20	$4.20	24	3
2023	$42,378.60	$6.07	31	4

Note: Value projections are illustrative only. All estimates and forward-looking projections are based on modeled assumptions, which we believe to be reasonable, and evidence based where applicable. However, such assumptions are subject to change based on newly emerging data and/ or evidence, which could lead to changes in some or all projections presented in this presentation. We disclaim any responsibility to update these projections in the event of such changes at any time in the future.

[1] Per token value is calculated based on the total SMPT supply of 1,000,000,000 tokens, and is adjusted for a projected pass-through of 5% and 15% of market value to SMPT token holders, for value deriving from commercialization and out-licensing strategies respectively.

SMARTPHARMA

DISCLAIMER

SMTPH Limited and Smart Pharmaceutical Limited Partnership, along with their affiliates, (the "Company") cannot guarantee the accuracy of the statements made or conclusions reached in this presentation. The Company does not make and expressly disclaims all representations and warranties (whether express or implied by statute or otherwise) whatsoever, including but not limited to: any representations or warranties relating to merchantability, fitness for a particular purpose, description, suitability or non-infringement; that the contents of this document are accurate and free from any errors; and that such contents do not infringe any third party rights.

The Company shall have no liability or damages of any kind arising out of the use, reference to or reliance on the contents of this presentation. This presentation may contain references to third-party data and industry publications. As far as the Company is aware, the information reproduced in this presentation is accurate and that its estimates and assumptions are reasonable. However, there are no assurances as to the accuracy or completeness of such information.

This presentation does not constitute a prospectus or offering document and is not an offer to sell, nor the solicitation of an offer to buy, any investment or financial instrument in any jurisdiction.

FORWARD-LOOKING STATEMENTS

This presentation contains forward-looking statements or information (collectively "Forward-Looking Statements") that relate to the Company's current expectations and views of future events. In some cases, these Forward-Looking Statements can be identified by words or phrases such as "may", "will", "expect", "anticipate", "aim", "estimate", "intend", "plan", "seek", "believe", "potential", "continue", "is/are likely to" or the negative of these terms, or other similar expressions intended to identify Forward-Looking Statements.

The Company has based these Forward-Looking Statements on its current expectations and projections about future events that it believes may affect its financial condition, results of operations, business strategy, financial needs or the valuation of the Smart-ACT™ program. This presentation also contains Forward-Looking Statements related to the Company's proposed operating model. The model speaks to its objectives only, and is not a forecast, projection or prediction of future results of operations. Forward-Looking Statements are based on certain assumptions and analysis made by the Company in light of its experience and perception of historical trends, current conditions and expected future developments and other factors it believes are appropriate, and are subject to risks and uncertainties. Although the Forward-Looking Statements contained in this presentation are based upon what the Company believes are reasonable assumptions, these risks, uncertainties, assumptions, and other factors could cause the Company's actual results, performance, achievements, and experience to differ materially from its expectations which are expressed, implied, or perceived in Forward-Looking Statements.

LEGAL NOTICES & RISK FACTORS

Nothing in this presentation shall be deemed to constitute a prospectus of any sort, a solicitation for investment or investment advice nor does it in any way pertain to an offering or a solicitation of an offer to buy any securities in any jurisdiction.

This presentation is not composed in accordance with, and is not subject to, laws or regulations of any jurisdictions which are designed to protect investors. To the maximum amount permitted by applicable law, the Company and its affiliates expressly disclaim and shall not be liable for any and all responsibility for any direct or any indirect, special, incidental, consequential or other losses of any kind, in tort, contract or otherwise (including but not limited to loss of revenue, income or profits, and loss of use or data).

All statements, estimates and financial information contained in this presentation on http://www.SMTPH.com, made in any press releases or in any place accessible by the public and oral statements that may be made by the Company or its affiliates that are not statements of historical fact, constitute Forward-Looking Statements. Nothing contained in this presentation is or may be relied upon as a promise, representation or undertaking as to the future performance or policies of the Company.

Further, the Company disclaims any responsibility to update any of these Forward-Looking Statements or publicly announce any revisions to these Forward-Looking Statements to reflect future developments, events or circumstances, even if new information becomes available or other events occur in the future. No regulatory authority has yet examined or approved any of the information set out in this presentation. No such action has been taken under the laws, regulatory requirements or rules of any jurisdiction.

The publication, distribution or dissemination of this presentation does not imply that any such applicable laws, regulatory requirements or rules have been complied with. Any person or entity, including anyone acting on its behalf, being based, being a citizen or resident, domiciled, located or incorporated where applicable laws prohibit or restrict distribution or dissemination of this presentation and other materials, otherwise such person assumes all the responsibility and legal consequences arising from such actions.

No guarantee that the Smart-ACT™ program and the drug candidates obtained from it will be developed

There is no guarantee or representation or warranty by the Company and its affiliates that: (i) the Smart-ACT™ program and the drug candidates obtained from it, (ii) the Smart-ACT™ program will perform as expected and without modifications, (iii) the drug candidates obtained from it will ever be licensed, developed or commercialized. The valuation of the Smart-ACT™ in this presentation is highly speculative and are subject to the satisfaction of all assumptions. Even if all assumptions are met, there is no guarantee that the Smart-ACT™ will make the estimated income and valuation hereunder.

Success of the Smart-ACT™ program depends on its continued innovation to identify existing drug compounds with potential second indications. As a result, the Company must continuously invest significant resources in research and development to enhance the Smart-ACT™ program and to develop the drug candidates obtained from it. If the Smart-ACT™ program is unable to effectively identify therapeutic targets for the chemical compounds, to discover sufficient candidates, or to attract collaborators or investors, the Company's business, income, results of operations and financial condition would be harmed.

In addition, successful commercialization of candidates obtained from the Smart-ACT™ program will depend on the ability for the Company and its affiliates to attract potential licensee to develop and commercialized those candidates.

The Smart-ACT™ program's existing and potential competitors include, but are not limited to, competing companies that operate, or could use AI or machine learning, to assist on drug discovery. These competing companies could devote greater technical and other resources than the Company and its affiliates have available, have a more accelerated timeframe for deployment and leverage their technologies to provide products and services that are viewed as superior to the Smart-ACT™ program. Any of the Smart-ACT™ program's future or existing competitors may introduce different solutions that provide solutions similar to it but with better branding or marketing resources.

If the Smart-ACT™ program fails to innovate, its business, results of operations and financial conditions may be negatively impacted. Further, the Smart-ACT™ program is still undergoing development while significant shifts in custom and use habits occur constantly and rapidly. The Company and its affiliates may not successfully anticipate or keep pace with industry changes, and it may invest considerable financial, personnel and other resources to pursue strategies that may not, ultimately, prove effective such that its business, results of operations and financial conditions may be harmed. The potential regulatory pathways for the candidates obtained from the Smart-ACT™ program may be affected by local, regional, national and international changes in regulations on drug approval process.